论文部分内容阅读
目的：评价重组人粒细胞集落刺激因子（Ｇ＿ＣＳＦ）在治疗肾移植后白细胞减少症中的效果及安全性。方法：应用Ｇ＿ＣＳＦ治疗肾移植后白细胞减少症１０例（男性６例，女性４例，年龄３８±ｓ１１ａ），每例注射Ｇ＿ＣＳＦ１５０μｇ，ｓｃ，ｑｄ，直至白细胞计数＞４×１０９／Ｌ。结果：１０例接受Ｇ＿ＣＳＦ的剂量为２２５±１０６μｇ，治疗前白细胞计数基值为（２．２±０．４）×１０９／Ｌ，治疗后白细胞峰值为（１０．６±２．６）×１０９／Ｌ（Ｐ＜０．０１），开始治疗至出现峰值时间为３．６±１．３ｄ，治疗前血清肌酐为２３５±１３５μｍｏｌ／Ｌ，治疗后２ｗｋ内最高血清肌酐为２３４±１２５μｍｏｌ／Ｌ（Ｐ＞０．０５）。结论：Ｇ＿ＣＳＦ治疗肾移植后白细胞减少症疗效显著，且不引起排斥反应
Objective: To evaluate the efficacy and safety of recombinant human granulocyte-colony stimulating factor (G_CSF) in the treatment of leukopenia after renal transplantation. Methods: 10 cases of leukopenia after renal transplantation (6 males and 4 females, age 38 ± s11a) were treated with G_CSF. G_CSF150μg, sc and qd were injected in each case until the white blood cell count> 4 × 109 / L. Results: The dose of G_CSF in 10 patients was 225 ± 106μg, the baseline value of white blood cell count before treatment was (2.2 ± 0.4) × 109 / L, the peak value of white blood cells after treatment was (10.6 ± 2.6) × 109 /L(P<0.01). The peak time was 3.6 ± 1.3d after initiation of treatment, the serum creatinine was 235 ± 135μmol / L before treatment, and the highest serum creatinine was 234 ± 125μmol / L within 2wk P> 0.05). Conclusion: G_CSF treatment of leukopenia after renal transplantation significant effect, and does not cause rejection